KAE may increase the capacity of chronic myeloid leukemia (CML) cells to withstand the pro-apoptotic effects of anti-TRAIL antibodies (Saraei et al., 2022). The gene discussed is TNFSF10; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.